A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
Open Access
- 25 September 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 23 (1), 212-214
- https://doi.org/10.1038/leu.2008.260
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLLLeukemia, 2008
- Emerging therapy for chronic lymphocytic leukaemiaBritish Journal of Haematology, 2007
- p53 Inactivation in CLL: Pattern of 110 TP53 Mutations.Blood, 2007
- Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialThe Lancet, 2007
- Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational statusBlood, 2007
- Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defectsLeukemia, 2006
- Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factorsBlood, 2002
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000